<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="211722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330447</url>
  </required_header>
  <id_info>
    <org_study_id>cancer in pregnancy</org_study_id>
    <nct_id>NCT00330447</nct_id>
  </id_info>
  <brief_title>Effects of Oncological Treatment During Pregnancy</brief_title>
  <official_title>Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laurence Claes, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingrid Boere, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael Halaska, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lagae, Lieven, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mertens, Luc, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monica Fumagalli, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers aim to investigate the outcome (overall survival) of mothers who are
      diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the
      hypothesis that children who were exposed to cytotoxic drugs in utero, or radiotherapy,
      develop normally (neurologic and cardiologic examination).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospectively the outcome of mothers diagnosed and/or treated for cancer during pregnancy
      will be registered and investigated.

      In a prospective trial we invite children that were exposed to cytotoxic drugs or
      radiotherapy in utero for a standardized neurological and cardiological examination. The
      examinations will be done by qualified psychologists, neurological and cardiological
      pediatricians.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Years</target_duration>
  <primary_outcome>
    <measure>Follow-up of the mothers diagnosed with cancer during pregnancy</measure>
    <time_frame>anticipated</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of the children antenatally exposed to chemotherapy or radiotherapy</measure>
    <time_frame>anticipated</time_frame>
    <description>neurologic and cardiologic outcome</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cancer</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Studygroup</arm_group_label>
    <description>Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Children from the general population</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and sediment of blood; from 2010 on we collect umbilical cord blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women diagnosed with cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following inclusion criteria:

          -  Histologically proven cancer during pregnancy

          -  Patients must have adequate bone marrow, renal, hepatic and pulmonary function.

          -  World Health Organization (WHO) performance status of 0 or 1

          -  &gt; 18 years of age

          -  Patients who have given their signed and written informed consent to participate in
             the trial after fully understanding the implication of the protocol

          -  Women receiving any cytotoxic drug during pregnancy are allowed for the assessment of
             the maternal and fetal outcome

          -  Patients are allowed to opt for the pharmacokinetic part or clinical follow-up part
             of the study only and do not need to participate in both; however, preferentially
             both study parts should be performed.

          -  Women receiving any kind of radiotherapy during pregnancy

        Exclusion Criteria:

          -  Mentally disabled or significantly altered mental status that would prohibit the
             understanding and giving of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amant Frederic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KULeuven, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liesbeth Leemans</last_name>
    <phone>+32-16-344634/5</phone>
    <email>Liesbeth.leemans@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristel Van Calsteren, MD PhD</last_name>
    <phone>+32-16-346192</phone>
    <email>kristel.vancalsteren@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Gasthuisberg, Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Amant, MD, PhD</last_name>
      <phone>+32-16-344252</phone>
      <email>frederic.amant@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Kristel Van Calsteren, MD, PhD</last_name>
      <phone>+32-16-346192</phone>
      <email>kristel.vancalsteren@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lieven Lagae, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Mertens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic Amant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristel Van Calsteren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Boere, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Halaska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence Claes, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Fumagalli, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.cancerinpregnancy.org</url>
    <description>This site provides background information on the problem of cancer in pregnancy and details further the project.</description>
  </link>
  <reference>
    <citation>Caluwaerts S, VAN Calsteren K, Mertens L, Lagae L, Moerman P, Hanssens M, Wuyts K, Vergote I, Amant F. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):905-8.</citation>
    <PMID>16681782</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, Claus P, Mertens L, Lagae L, Delforge M, Paridaens R, Noens L, Humblet Y, Vandermeersch B, De Muylder X. In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J Clin Oncol. 2006 Apr 20;24(12):e16-7.</citation>
    <PMID>16622256</PMID>
  </reference>
  <reference>
    <citation>Vandenbroucke T, Van Calsteren K, Amant F. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2016 Feb 18;374(7):693. doi: 10.1056/NEJMc1515462.</citation>
    <PMID>26886537</PMID>
  </reference>
  <reference>
    <citation>Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. J Clin Oncol. 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445. Epub 2015 Nov 30.</citation>
    <PMID>26628463</PMID>
  </reference>
  <reference>
    <citation>Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, Han S, Gziri MM, Peccatori F, Rob L, Lok C, Witteveen P, Voigt JU, Naulaers G, Vallaeys L, Van den Heuvel F, Lagae L, Mertens L, Claes L, Van Calsteren K; International Network on Cancer, Infertility, and Pregnancy (INCIP).. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2015 Nov 5;373(19):1824-34. doi: 10.1056/NEJMoa1508913. Epub 2015 Sep 28.</citation>
    <PMID>26415085</PMID>
  </reference>
  <reference>
    <citation>Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, Van Den Bogaert K, Dierickx D, Vandecaveye V, Tousseyn T, Moerman P, Vanderstichele A, Vergote I, Neven P, Berteloot P, Putseys K, Danneels L, Vandenberghe P, Legius E, Vermeesch JR. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. JAMA Oncol. 2015 Sep;1(6):814-9. doi: 10.1001/jamaoncol.2015.1883.</citation>
    <PMID>26355862</PMID>
  </reference>
  <reference>
    <citation>Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015 Nov;1(8):1145-53. doi: 10.1001/jamaoncol.2015.2413. Erratum in: JAMA Oncol. 2015 Nov;1(8):1172.</citation>
    <PMID>26247818</PMID>
  </reference>
  <reference>
    <citation>de Haan J, Verheecke M, Amant F. Management of ovarian cysts and cancer in pregnancy. Facts Views Vis Obgyn. 2015;7(1):25-31. Review.</citation>
    <PMID>25897369</PMID>
  </reference>
  <reference>
    <citation>Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M, Van Calsteren K. Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015 Jul;29(5):741-53. doi: 10.1016/j.bpobgyn.2015.02.006. Epub 2015 Mar 4. Review.</citation>
    <PMID>25797199</PMID>
  </reference>
  <reference>
    <citation>van Dam L, Han SN, Dierickx D, Amant F. Optimal staging of lymphoma during pregnancy is crucial. Womens Health (Lond). 2015 Mar;11(2):101-2. doi: 10.2217/whe.14.77.</citation>
    <PMID>25776282</PMID>
  </reference>
  <reference>
    <citation>Han SN, Van Peer S, Peccatori F, Gziri MM, Amant F; International Network on Cancer, Infertility and Pregnancy.. Contraception is as important as fertility preservation in young women with cancer. Lancet. 2015 Feb 7;385(9967):508. doi: 10.1016/S0140-6736(15)60201-X.</citation>
    <PMID>25705843</PMID>
  </reference>
  <reference>
    <citation>Vandenbroucke T, Amant F. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015 Jun;212(6):830-1. doi: 10.1016/j.ajog.2015.01.035. Epub 2015 Jan 28.</citation>
    <PMID>25637847</PMID>
  </reference>
  <reference>
    <citation>Vandenbroucke T, Verheecke M, Van Calsteren K, Han S, Claes L, Amant F. Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking. Expert Opin Drug Saf. 2014 Dec;13(12):1653-65. doi: 10.1517/14740338.2014.965677. Epub 2014 Nov 10. Review.</citation>
    <PMID>25382454</PMID>
  </reference>
  <reference>
    <citation>Han SN, Verheecke M, Vandenbroucke T, Gziri MM, Van Calsteren K, Amant F. Management of gynecological cancers during pregnancy. Curr Oncol Rep. 2014 Dec;16(12):415. doi: 10.1007/s11912-014-0415-z. Review.</citation>
    <PMID>25344340</PMID>
  </reference>
  <reference>
    <citation>van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014 Oct;25(10):2059-65. doi: 10.1093/annonc/mdu140. Epub 2014 Apr 8.</citation>
    <PMID>24713311</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Amant F. Cancer during pregnancy. Acta Obstet Gynecol Scand. 2014 May;93(5):443-6. doi: 10.1111/aogs.12380.</citation>
    <PMID>24628416</PMID>
  </reference>
  <reference>
    <citation>Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, Han SN, Mir O, Fruscio R, Uzan C, Maxwell C, Dekrem J, Strauven G, Mhallem Gziri M, Kesic V, Berveiller P, van den Heuvel F, Ottevanger PB, Vergote I, Lishner M, Morice P, Nulman I; ESGO task force ‘Cancer in Pregnancy’.. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014 Mar;24(3):394-403. doi: 10.1097/IGC.0000000000000062. Review. Erratum in: Int J Gynecol Cancer. 2014 May;24(4):819.</citation>
    <PMID>24445819</PMID>
  </reference>
  <reference>
    <citation>Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs. 2013 Oct;15(5):329-34. doi: 10.1007/s40272-013-0040-6. Review.</citation>
    <PMID>23856754</PMID>
  </reference>
  <reference>
    <citation>Vandenbriele C, Dierickx D, Amant F, Delforge M. The treatment of hematologic malignancies in pregnancy. Facts Views Vis Obgyn. 2010;2(2):74-87. Review.</citation>
    <PMID>25302102</PMID>
  </reference>
  <reference>
    <citation>Deckers S, Amant F. Breast cancer in pregnancy: a literature review. Facts Views Vis Obgyn. 2009;1(2):130-41. Review.</citation>
    <PMID>25478078</PMID>
  </reference>
  <reference>
    <citation>Gziri MM, Goffin F, Debieve F, Amant F. [Cancer diagnosis during pregnancy: importance of a national and European registration]. Rev Med Liege. 2013 Oct;68(10):527-30. French.</citation>
    <PMID>24298727</PMID>
  </reference>
  <reference>
    <citation>Gziri MM, Pokreisz P, De Vos R, Verbeken E, Debiève F, Mertens L, Janssens SP, Amant F. Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment. J Pharmacol Exp Ther. 2013 Sep;346(3):362-9. doi: 10.1124/jpet.113.205419. Epub 2013 Jun 21.</citation>
    <PMID>23792410</PMID>
  </reference>
  <reference>
    <citation>Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F; ESGO ‘Cancer in Pregnancy’ Task Force.. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):18-23. doi: 10.1016/j.ejogrb.2012.10.026. Epub 2012 Nov 19.</citation>
    <PMID>23182070</PMID>
  </reference>
  <reference>
    <citation>Han SN, Gziri MM, Van Calsteren K, Amant F. Is chemotherapy during the first trimester of pregnancy really safe? Int J Cancer. 2013 Apr 1;132(7):1728. doi: 10.1002/ijc.27815. Epub 2012 Sep 28.</citation>
    <PMID>22945483</PMID>
  </reference>
  <reference>
    <citation>Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012 Aug 8;10:86. doi: 10.1186/1741-7015-10-86.</citation>
    <PMID>22873292</PMID>
  </reference>
  <reference>
    <citation>Loibl S, Han SN, Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel). 2012 Jun;7(3):204-209. Epub 2012 Jun 27.</citation>
    <PMID>22872793</PMID>
  </reference>
  <reference>
    <citation>Amant F. Safety of chemotherapy in pregnancy. Clin Adv Hematol Oncol. 2012 Apr;10(4):258-9.</citation>
    <PMID>22706488</PMID>
  </reference>
  <results_reference>
    <citation>Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, Halaska M, Vergote I, Ottevanger N, Amant F. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010 Feb 1;28(4):683-9. doi: 10.1200/JCO.2009.23.2801. Epub 2009 Oct 19.</citation>
    <PMID>19841323</PMID>
  </results_reference>
  <results_reference>
    <citation>Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H, Heyns L, Han SN, Tomek V, Mertens L, Ottevanger PB. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012 Mar;13(3):256-64. doi: 10.1016/S1470-2045(11)70363-1. Epub 2012 Feb 10.</citation>
    <PMID>22326925</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Debiève F, DE Catte L, Mertens L, Barrea C, VAN Calsteren K, Han SN, Heyns L, Amant F. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstet Gynecol Scand. 2012 Dec;91(12):1465-8. doi: 10.1111/j.1600-0412.2012.01524.x. Epub 2012 Nov 1.</citation>
    <PMID>22880883</PMID>
  </results_reference>
  <results_reference>
    <citation>Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012 Sep;13(9):887-96. doi: 10.1016/S1470-2045(12)70261-9. Epub 2012 Aug 16.</citation>
    <PMID>22902483</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Amant F, Debiève F, Van Calsteren K, De Catte L, Mertens L. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat Diagn. 2012 Jul;32(7):614-9. doi: 10.1002/pd.3847. Epub 2012 Apr 17. Review.</citation>
    <PMID>22508540</PMID>
  </results_reference>
  <results_reference>
    <citation>Mhallem Gziri M, Han SN, Van Calsteren K, Heyns L, Delaere P, Nuyts S, Van den Heuvel F, Cheron AC, Fossion E, Van den Weyngaert D, Lok C, Amant F. Tongue cancers during pregnancy: Case reports and review of literature. Head Neck. 2013 Apr;35(4):E102-8. doi: 10.1002/hed.21924. Epub 2011 Oct 19. Review.</citation>
    <PMID>22009853</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Hui W, Amant F, Van Calsteren K, Ottevanger N, Kapusta L, Mertens L. Myocardial function in children after fetal chemotherapy exposure. A tissue Doppler and myocardial deformation imaging study. Eur J Pediatr. 2013 Feb;172(2):163-70. doi: 10.1007/s00431-012-1849-7. Epub 2012 Oct 5.</citation>
    <PMID>23052619</PMID>
  </results_reference>
  <results_reference>
    <citation>Boussios S, Han SN, Fruscio R, Halaska MJ, Ottevanger PB, Peccatori FA, Koubková L, Pavlidis N, Amant F. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013 Dec;82(3):499-505. doi: 10.1016/j.lungcan.2013.09.002. Epub 2013 Sep 12.</citation>
    <PMID>24091171</PMID>
  </results_reference>
  <results_reference>
    <citation>Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013 Jul 10;31(20):2532-9. doi: 10.1200/JCO.2012.45.6335. Epub 2013 Apr 22.</citation>
    <PMID>23610117</PMID>
  </results_reference>
  <results_reference>
    <citation>Verheecke M, Halaska MJ, Lok CA, Ottevanger PB, Fruscio R, Dahl-Steffensen K, Kolawa W, Gziri MM, Han SN, Van Calsteren K, Van den Heuvel F, De Vleeschouwer S, Clement PM, Menten J, Amant F; ESGO Task Force ‘Cancer in Pregnancy’.. Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature. Eur J Cancer. 2014 May;50(8):1462-71. doi: 10.1016/j.ejca.2014.02.018. Epub 2014 Mar 14. Review.</citation>
    <PMID>24636876</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 18, 2016</lastchanged_date>
  <firstreceived_date>May 25, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Frederic Amant</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>in utero</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>cancer</keyword>
  <keyword>offspring</keyword>
  <keyword>neonatal</keyword>
  <keyword>long term</keyword>
  <keyword>follow up</keyword>
  <keyword>cancer during pregnancy</keyword>
  <keyword>chemotherapy and radiotherapy during pregnancy</keyword>
  <keyword>long term follow up of children</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
